Renal denervation for hypertension: Observations and predictions of a founder

European Heart Journal

Volumn 35, Issue 18, 2014, Pages 1178-1185

  Esler, Murray ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Hypertension pathogenesis; Renal denervation

Indexed keywords

ANTIHYPERTENSIVE AGENT; IMIDAZOLINE DERIVATIVE; PHENOL; SODIUM; ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BORDERLINE HYPERTENSION; CARDIOVASCULAR DISEASE; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CLINICAL OBSERVATION; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY FAILURE; KIDNEY FUNCTION TEST; KIDNEY TUBULE ABSORPTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PATIENT CARE; PATIENT SAFETY; PATIENT SELECTION; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RENOVASCULAR HYPERTENSION; RESISTANT HYPERTENSION; REVIEW; RISK REDUCTION; SODIUM INTAKE; SYMPATHETIC NERVE; TREATMENT FAILURE; WHITE COAT HYPERTENSION; DRUG RESISTANCE; ENDOVASCULAR SURGERY; HYPERTENSION, RENAL; INNERVATION; KIDNEY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SYMPATHECTOMY;

ADRENERGIC AGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE; ENDOVASCULAR PROCEDURES; HUMANS; HYPERTENSION, RENAL; KIDNEY; PATIENT SELECTION; SYMPATHECTOMY;

EID: 84900321398     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu091     Document Type: Review

References (62)

1. Zimmer K. Soul Made Flesh. London: The Random House (Arrow Books), 2004, pp. 188-207.
2. Hamilton WF, Richards DW. Output of the heart. In: Fishman AP, Richards DW (eds), Circulation of the Blood. Men and Ideas. Bethesda: American Physiological Society, 1982, pp. 87-90.
3. Julius S, Esler M. The Nervous System in Arterial Hypertension. Springfield, IL: Charles C. Thomas, 1976.
4. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1, 266 cases. J Am Med Assoc 1953;152:1501-1504.
5. Paton WDM, Zaimis EJ. Paralysis of autonomic ganglia by methonium salts. Brit J Pharmacology 1951;6:155-168.
6. van Zwieten PA. Development of antihypertensive drugs: from the bench to the clinic. Handbook of Hypertension, Chapter 22. In: Birkenhager WH, Robertson JIS, Zanchetti A (eds), Hypertension in the Twentieth Century: Concepts and Achievements. Amsterdam: Elesvier, 2004, pp. 457-486.
7. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clement D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of european guidelines on hypertension management: A European Society of Hypertension Task Force Document. J Hypertens 2009;27:2121-2158.
8. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011;57: 898-902.
9. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011;57:1076-1080.
10. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension. J Am Coll Cardiol 2011;58:765-773.
11. Krum H, Schlaich MP, Whitbourn R, Sobotka P, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-1281.
12. Symplicity HTN-2 Investigators. Renal sympathetic denervationin patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial (Chief Investigator and Corresponding Author). Lancet 2010;376: 1903-1909.
13. Esler M, Jennings G, Korner P, Blombery P, Sacharias N, Leonard P. Measurement of total and organ-specific norepinephrine kinetics in humans. Am J Physiol 1984; 247(Endocrinol Metab 10):E21-E28.
14. Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, Anderson W, Lambert G. The assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988;11:3-20.
15. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension 1989;14:177-183.
16. Grassi G, Colombo M, Seravalle G, Spaziani D, Mancia G. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension 1998;31:64-67.
17. Lambert E, Straznicky N, Schlaich MP, Dawood T, Hotchkin E, Esler MD, Lambert GW. Differing patterns of sympathoexcitation in normal weight and obesity-related hypertension. Hypertension 2007;50:862-868.
18. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal de-nervation. Am J Physiol (Regul Integr Comp Physiol) 2012;298:R245-R253.
19. DiBona GF, Kopp UC. Neural controlof renal function. Physiol Rev 1997;77:75-197.
20. DiBona GF. The functionsof the renal nerves. Rev Physiol Biochem Pharmacol 1982;94: 75-181.
21. Huggett RJ, Burns J, MackIntosh AF, Mary DASG. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 2004;44:1-6.
22. Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, Wiesner GH, Brunner-La Rocca HP, Esler MD. Neural mechanisms in human obesity-related hypertension. J Hypertens 1999;17:1125-1133.
23. Roman RJ, Cowley AW. Characterisation of a new model for the study of pressure natriuresis in the rat. Am J Physiol Renal Physiol 1985;248:F190-F198.
24. Oldham JB. Denervation of the kidney. Hunterian Lecture of the Royal College of Surgeons, England. 9th March 1950. Ann R Coll Surg Engl 1950;7:222-245.
25. Rippy MK, Zarins D, Barman NC, Wu A, Duncan KL, Zarins CK. Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin Res Cardiol 2011;100:1095-1101.
26. Krum H, Schlaich MP, Bohm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervationin patients with treatment-resistant hypertension: final 3-yer report of the Symplicity HTN-1 study. Lancet 2013. doi: 10.1016/S0140-6736(13)62192-3.
27. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA. Renal denerv-ation for treatment of drug-resistant hypertension. One-year results from the Sym-plicity HTN-2 randomized, controlled trial. Circulation 2012;126:2976-2982.
28. Investigators Symplicity HTN-1. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011;57:911-917.
29. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 2013. [Epub ahead of print].
30. Ormiston JA, Watson T, van Pelt N, Stewart JT, White JM, Doughty RN, Stewart F, Macdonald R, Webster MW. Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) trial. Euro Intervention 2013;9:70-74.
31. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic nerve ablation for treatment of uncontrolled hypertension. N Engl J Med 2009;361: 932-934.
32. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation inpatients with resistant hypertension. Hypertension 2013;61:457-464.
33. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995;25:878-882.
34. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J. Med. 1992;327:1912-1918.
35. Esler M, Lux A, Jennings G, Hastings J, Socratous F, Lambert G. Rilmenidine sympatholytic activity preserves mental stress, orthostatic sympathetic responses and adrenaline secretion. J Hypertens 2004;22:1529-1534.
36. Ukena C, Mahfoud F, Kindermann I, Barth C, Kindermann M, Brandt M-C, Hoppe UC, Krum H, Esler M, Sobotka P, Bohm M. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol 2011;58:1176-1182.
37. Mahfoud F, Lenski M, Ukena C, Barth C, Razouk A, Fischer D, Laufs U, Kindermann I, Böhm M. Influence of renal sympathetic denervation on orthostatic function in patients with resistant hypertension. Circulation 2012;126:A17201.
38. Mahfoud F, Ukena C, Schmieder R, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka P, Krum H, Schlaich M, Esler M, Bohm M. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013;128: 132-140.
39. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens 2004;22: 435-445.
40. Jennings G, Esler M, Korner P. Effect of prolonged treatment on haemodynamics of essential hypertension before and after autonomic block. Lancet 1980;2:166-169.
41. Brandt MC, Reda S, Mahfoud F, Lenski M, Böhm M, Hoppe UC. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol 2012;60:1956-1965.
42. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, Hoppe UC. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012;59:901-909.
43. Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension 2012;60:596-606.
44. Esler M, Lambert E, Schlaich M. PointCounterpoint Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.J Appl Physiol 2010;109:1996-1998.
45. Steigerwald K, Titova A, Malle C, Kennerknecht EJilek C, Hausleiter J, Nährig JM, Laugwitz KL, Joner M. Morphological assessment of renal arteries after radiofre-quency catheter-based sympathetic denervation in a porcine model. J Hypertens 2012;30:2230-2239.
46. TM multi-electrode renal denervation catheter. Eur Heart J 2013;34:2141-2148.
47. Vonend O, Antoch G, Rump LC, Blondin D. Secondary rise in blood pressure after renal denervation. Lancet 2012;380:778.
48. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervationon glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011;123:1940-1946.
49. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, Shirokova N, Karaskov A, Mittal S, Steinberg JS. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012;60:1163-1170.
50. Witkowski A, Prejbisz A, Florczak E, Ka̧dziela J, Sliwiński P, Bieleń P, Michałowska I, Kabat M, Warchoł E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011;58:559-565.
51. Lambert GW, Hering D, Esler MD, Marusic P, Lambert EA, Tanamas SK, Shaw J, Krum H, Dixon JB, Barton DA, Schlaich MP. Health-related quality of life after renal denervation inpatients with treatment-resistant hypertension. Hypertension 2012. doi:10.1161/hypertensionaha.112.00865.
52. Yumino D, Redolfi S, Ruttanaumpawan P, Su M-C, Smith S, Newton G, Mak S, Bradley D. Nocturnal rostral fluid shift. A unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation 2010;121: 1598-1605.
53. Hansson L. Are there benefits from any antihypertensive agent additional to blood pressure lowering per se?. Handbook of Hypertension, Chapter 24. In: Birkenhager WH, Robertson JIS, Zanchetti A (eds), Hypertension in the Twentieth Century: Concepts and Achievements. Amsterdam: Elesvier, 2004, pp. 526-554.
54. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH)and of the European Society of Cardiology (ESC), Co-Chairs Manci G, Fagard R. ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013;31:1281-1357.
55. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka P, Bohm M, Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012;23:1250-1257.
56. Schlaich MP, Bart B, Hering D, Walton A, Marusic P, Mahfoud F, Bohm M, Lambert EA, Krum H, Sobotka P, Schmieder RE, Ika-Sara C, Eikelis N, Straznicky N, Lambert GW, Esler MD. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiology 2013. doi:10.1016/j.ijcard.2013.01. 218.
57. Kopp UC, Smith LA, DiBona GF. Renorenal reflexes: neural components of ipsilat-eral and contralateral renal responses. Am J Physiol 1985;249:F507-F517.
58. Parati G, Esler M. The human sympathetic nervous system: Its relevancein hypertension and heart failure. Eur Heart J 2012;33:1058-1066.
59. Koepke JP, DiBona GF. High sodium intake enhances renal nerve and antinatriuretic responses to stress in SHR. Hypertension 1985;7:357-363.
60. Meredith IT, Friberg P, Jennings GL, Dewar EM, Fazio VA, Lambert GW, Esler MD. Regular exercise lowers renal but not cardiac sympathetic activity in man. Hypertension 1991;18:575-582.
61. Esler M, Eikelis N, Schlaich M, Lambert G, Alvarenga M, Dawood T, Kaye D, Barton D, Pier C, Guo L, Brenchley C, Jennings G, Lambert E. Chronic mental stressisacause of essential hypertension: presence of biological markers of stress. Clin Exp Pharm Physiol 2008;35:498-502.
62. Hjemdahl P, Esler M. Cardiovascular and autonomic responses to stress. In: Hjemdahl P, Rosengren A, Steptoe A (eds), Stress and cardiovascular Disease. London: Springer-Verlag, 2012, pp. 31-53.